DWA
CBAY

Dorsey Wright & Associates’s Cymabay Therapeutics CBAY Stock Holding History

Dorsey Wright & Associates’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,956
Closed -$88.8K – 305
2023
Q3 		$88.8K Sell
5,956
-206
-3% -$2.73K 0.03% 128
2023
Q2 		$67.5K Buy
6,162
+615
+11% +$5.73K 0.02% 130
2023
Q1 		$48.4K Sell
5,547
-615
-10% -$4.92K 0.01% 130
2022
Q4 		$38.6K Buy
+6,162
New +$23.4K 0.01% 146

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dorsey Wright & Associates's CBAY Position: Q4 2023 in Review

Dorsey Wright & Associates sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 5,956 shares — an estimated $88.8K sold.

Dorsey Wright & Associates first reported a position in CBAY in Q4 2022 and held it in 4 quarters. The position peaked at $88.8K in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Dorsey Wright & Associates reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 5,956 Cymabay Therapeutics shares in Q4 2023, an estimated $88.8K.
  • Dorsey Wright & Associates first reported a position in Cymabay Therapeutics in Q4 2022 and held it in 4 quarters.
  • Dorsey Wright & Associates's Cymabay Therapeutics position peaked at $88.8K in Q3 2023.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Dorsey Wright & Associates's 13F filing for Q4 2023, filed 13 Feb 2024.